Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

13 October 2014 PLASMA DONORS RECOGNIZED DURING INTERNATIONAL PLASMA AWARENESS WEEK FOR HELPING SAVE LIVES

CSL Behring and its subsidiary, CSL Plasma, join the Plasma Protein Therapeutics Association (PPTA) in saluting the contributions of plasma donors during International Plasma Awareness Week (IPAW), celebrated October 12-18.

> Read More
08 October 2014 CSL Behring Launches $450 Million Capacity Expansion to Meet Growing Need for Lifesaving, Life-Improving Therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.

> Read More
30 September 2014 CSL Behring Expands Manufacturing Facility in Kankakee, Illinois to Meet Patients' Growing Needs

CSL Behring announced that it is set to commence operations in its newly expanded facility now that the U.S. Food & Drug Administration (FDA) has granted approval. The expansion significantly increases plasma processing and albumin production capacity in the Kankakee, Ill. facility.

> Read More
16 September 2014 CSL Behring Announces Last Patient Treated in Phase III Study of Fibrinogen Concentrate to Control Bleeding During Aortic Aneurysm Surgery

CSL Behring announced today that the last patient has been treated as part of the REPLACE (Randomized Evaluation of fibrinogen versus PLACEbo in complex cardiovascular surgery) Phase III clinical trial. REPLACE is the first randomized, double blinded, placebo-controlled, multicenter study in a large population of patients evaluating fibrinogen concentrate (Human) (FCH) in controlling bleeding during aortic aneurysm surgery.

> Read More
18 August 2014 Early Diagnosis of Children with Primary Immunodeficiencies Focus of National Awareness Campaign for School Nurses

School nurses reach 98 percent of the 50,000,000 students in U.S. public schools, grades k-12, and are uniquely positioned to facilitate the early diagnosis of serious medical conditions such as primary immunodeficiency (PI).

> Read More
Page 1 of 5 Next | Last

Share
LinkedIn Twitter Facebook Google+